Human papillomavirus (HPV) infection is associated with ∼5% of all human cancers, including a range of squamous cell carcinomas. Persistent infection by high-risk HPVs (HRHPVs) is associated with the integration of virus genomes (which are usually stably maintained as extrachromosomal episomes) into host chromosomes. Although HRHPV integration rates differ across human sites of infection, this process appears to be an important event in HPV-associated neoplastic progression, leading to deregulation of virus oncogene expression, host gene expression modulation, and further genomic instability. However, the mechanisms by which HRHPV integration occur and by which the subsequent gene expression changes take place are incompletely understood. The advent of next-generation sequencing (NGS) of both RNA and DNA has allowed powerful interrogation of the association of HRHPVs with human disease, including precise determination of the sites of integration and the genomic rearrangements at integration loci. In turn, these data have indicated that integration occurs through two main mechanisms: looping integration and direct insertion. Improved understanding of integration sites is allowing further investigation of the factors that provide a competitive advantage to some integrants during disease progression. Furthermore, advanced approaches to the generation of genome-wide samples have given novel insights into the three-dimensional interactions within the nucleus, which could act as another layer of epigenetic control of both virus and host transcription. It is hoped that further advances in NGS techniques and analysis will not only allow the examination of further unanswered questions regarding HPV infection, but also direct new approaches to treating HPV-associated human disease.
Introduction
Integration of high-risk human papillomavirus (HRHPV) into host cell chromosomes is seen in ∼85% of cervical squamous cell carcinomas (SCCs), and is viewed as a key driver of squamous carcinogenesis [1] . However, the cause and consequences of integration remain poorly understood. Most published studies of clinical samples and cell lines have used polymerase chain reaction (PCR)-based approaches to map integration sites. Amplification of HRHPV DNA (e.g. by restriction site PCR) or RNA [e.g. by rapid amplification of cDNA ends-PCR/amplification of papillomavirus oncogene transcripts] is limited by inherent technical bias, and the latter methods can only detect transcriptionally active virus integrants [2] . Recent studies based on next-generation sequencing (NGS) have allowed precise, unbiased mapping of HRHPV integration sites across large sample sets. The approaches used have included targeted methods [e.g. whole exome sequencing (WES) of DNA or polyA-specific RNA sequencing (mRNA-seq)], or untargeted, unbiased techniques [e.g. whole genome sequencing (WGS) of DNA or total RNA sequencing (RNA-seq)] (Table 1) . Newer targeted approaches have also been applied to great advantage, including Capture-Seq technologies based on enrichment of DNA itself prior to sequencing. Such methods can provide a deeper analysis of specific regions, including genome-wide promoter assessment [3] .
Large-scale studies to date have focused on tissue samples from the cervix or head and neck [4] [5] [6] [7] [8] [9] [10] , as well as SCC cell lines and the human papillomavirus (HPV) 18-positive cervical adenocarcinoma cell line HeLa [11] [12] [13] . This review will discuss insights provided by NGS into mechanisms of HRHPV integration and the effects on virus and host gene structure and expression in SCC cells. We will also consider the limitations of the 
NGS provides unbiased mapping of HRHPV integration sites
Multiple studies have employed NGS to determine the presence and location within the human host genome of virus integration in HRHPV-associated malignancies [14] (Figure 1 ). There are various approaches to investigations of this type, and many different bioinformatic strategies for dealing with the data, usually looking for virus-host chimeric fusion or paired-end reads ( Figure 2 ). Such differences are likely to explain the broad range of numbers of different integration sites reported across a spectrum of sample types. Most strikingly, one study using DNA sequencing (DNA-seq) (Capture-Seq and WGS) identified a range of 0-599 integrations, with a median of 8, per cervical SCC (CSCC) [5] . The upper limit to this range was much higher than seen in other studies, in which a maximum of 47 breakpoints was found by WGS in the CSCC line CaSki [12] . A likely explanation lies in the bioinformatic approach to data analysis, as lower-stringency searches and lack of confirmation by Sanger sequencing may give erroneously high integration rates [15] . Indeed, another Capture-Seq study found much lower levels of integration in similar sample types [16] . In contrast to DNA-seq, the output data from RNA-seq is limited to detecting actively transcribing HRHPV genomes. This approach showed 65 integration sites across 79 CSCCs, a rate of 82.3% [8] , which is consistent with subsequent analysis of expanded TCGA datasets, in which 83% of 169 HRHPV-positive CSCCs were found to harbour HRHPV integrants [4] . The use of into the distal host genome, producing a fusion transcript that can appear as a genuine breakpoint (Figure 2 ). This, in part, has led to up to 15 HPV18 integration sites being claimed in HeLa cells [17, 18] , whereas only four are usually confirmed [11, 13, 19] . The need for verification of NGS findings by Sanger sequencing applies to both RNA-seq and DNA-seq. Reanalysis of RNA-seq data showed that the finding of HPV18 association with a wide range of normal tissues and cancers [10, 20] had occurred erroneously, probably because of contamination of sequencing machines, as only RNA, and not DNA, matching the integrated form of HPV18 in HeLa was reported [21] . Similar contamination issues have been flagged in the TCGA datasets for RNA-seq from endometrial cancers, where an apparent batch contamination from one HPV38-positive sample may have taken place [22] . NGS has also been used to show that HeLa contamination of many nasopharyngeal cell lines has historically occurred [23] . This is also likely to be true for other as yet untested cell lines.
Rates of virus integration in HRHPV-associated malignancies have been claimed to distinguish CSCC (rate 86.5%, median 8, range 0-599 per sample) from adenocarcinomas (rate 53.3%, median 1, range 0-29 per sample) and also cervical intraepithelial neoplasias (CINs) (rate 53.8%, median 1, range 0-49 per sample) [5] . Highly sensitive Capture-Seq has also shown that HRHPV DNA integration in cervical lesions becomes more common with disease progression [16, 24] , suggesting that integration events may not be limited to the early stages of CSCC development [1] . Interestingly, using such a sensitive technique, these authors were able to show not just HRHPV infection of normal cervical epithelium samples, but also integration of HPV16 in one such sample at three different sites in the host genome [16] . In head and neck SCC (HNSCC) samples, HRHPV DNA was found at a much lower rate (13%) [9] than in CSCC, consistent with results from a further study of oropharyngeal SCC (OPSCC) using DNA mate-pair sequencing [25] . Integration sites in HNSCC could be mapped in only 25 of 279 cases studied, one of which had 16 discrete integration sites (rate 9%, range 0-16) [9] .
Although HPV can seemingly integrate at any point across the human genome, parallel sequencing of CSCC and HNSCC samples has identified some integration sites or 'hotspots' that are common in SCCs. Frequently observed genes occurring at or near such sites included ERBB2, NR4A2, RAD51B, and TP63, and genomic loci included 3q28, 13q22.1, and 8q24.21 (which harbours MYC and POU5F1B) [4] [5] [6] [8] [9] [10] 26] , confirming previous non-NGS work [27] . Previous work also showed that ∼50% of the integration sites in CSCC encompass, or are in close proximity to, common fragile sites, which are regions of the human genome that are disposed to breaking through DNA replication stress [2] . This has recently also been shown to occur in ∼50% of OPSCC samples containing integrated HRHPV, despite the overall frequency of HRHPV integration in such cases being low (∼30% of cases) [25, 26] . Integration in HRHPV-positive HNSCC was also found to be associated with microRNA (miRNA) clusters, as has previously been found in non-NGS studies [9, 28] , and within the coding region of long non-coding RNAs (lncRNAs) in CSCCs, including some within the 8q24 MYC gene locus [5, 8] .
Sites of frequent integration have been aligned with epigenetic NGS datasets, such as the Encyclopedia of DNA elements (ENCODE) [29] and the NIH Epigenome Roadmap [30] . This highlighted the correlation of HRHPV integration with areas of open chromatin and nucleosome depletion (defined by DNase hypersensitivity), and areas of active chromatin, including the H3K4me3 histone post-translational modification [14, [31] [32] [33] . Importantly, these epigenetically active locations may reflect integration sites that provide a cell-selective advantage in SCC, rather than being representative of integration loci that occur in the early stages of HRHPV-associated carcinogenesis [1] . Precise determination of integration sites with NGS has revealed that HPV16 integrant genomes can adopt the DNA methylation status of the local host genome in HNSCC, with the possibility that this affects virus gene expression [34] . It remains to be determined whether similar considerations apply to chromatin modifications.
Insights into the mechanism of HRHPV integration
One 'hotspot' of integration for more than one HRHPV type (HPV16, HPV18, and HPV52) shown by NGS is RAD51B [8, 9] . RAD51B functions in the DNA double-strand break repair response, a pathway that may, at least in part, dictate integration loci, and that has been found to be upregulated in HNSCC [9] . Indeed, there is increasing evidence that HRHPV drives integration through microhomology-mediated DNA repair pathways, with genome-wide studies of HNSCC and CSCC sequencing data confirming previous non-NGS findings [28] . Microhomology, i.e. an identical genomic nucleotide sequence, between the host and virus junctional sequences is commonly found across 1-10 bp [9, 12, 35] , with a peak in one study at 4 bp [5] . Intriguingly, the presence of a 4-bp length of microhomology occurs more often than expected as much as 100 bp away from the virus-host junctions, and has been described as 'flanking' microhomology [5] . Although the analysis of these data has been questioned [15] , reanalysis still indicated a microhomology rate of 43% across verified breakpoints [15] , and was supported by later work [19] . The enrichment of microhomology at HRHPV integration sites suggested that integration might occur through fork stalling and template switching or microhomology-mediated break-induced replication [5] . This was further supported by the finding that integration tends to occur more often than expected near to sites of local genomic instability, including satellite and short interspersed nuclear element-Alu sequences, which are possible catalysts for this repair mechanism [5] . An interesting development in our understanding of the process of integration has come from recent findings that, in HRHPV-positive OPSCC samples, integration junctions often contain AT-rich and repetitive sequences. Such sequences have the potential to form stem-loop secondary structures, and have been hypothesized to cause stalling of DNA polymerase during genome replication. This might lead to increased local genomic instability, especially when combined with expression of the HRHPV oncogenes E6 and E7, such that HRHPV integration and/or chromosome rearrangements could occur [26] .
In an important recent study, Akagi et al performed detailed analysis of both CSCC and HNSCC cell lines and tumours, using WGS and RNA-seq, as well as
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finer Sanger sequence mapping, PCR, and chromosome walking [12] . They found recurrent patterns of focal amplification and rearrangements adjacent to the integration sites, implying that concatemers of host and virus genome become amplified in tandem and reinserted back into the host genome. This has since been described as the 'looping' model, and has been corroborated in CSCC samples by Capture-Seq technology targeting all known HRHPV types [35] . Here, the use of >22 000 probes against the HRHPV sequence and subsequent NGS showed that, as well as the direct co-linear insertion of an HRHPV genome (including the deletion of flanking sequences), non-linear insertion of single genomes can occur. The latter leads to two virus-host junctions (5 ′ and 3 ′ ) or to multiple copies of virus and host flanks following amplification, consistent with the 'looping' model ( Figure 3) . Of potential clinical relevance was the finding that analysis of circulating tumour DNA from matched blood samples also confirmed the integration profile of each patient. Interestingly, it was also found that patients with tumours that had several distinct virus-host junctions (either in one locus or across several loci), or tumours in which HRHPV episomes remained, had improved overall survival rates and lower relapse rates (after 6 months of follow-up) than those with an integration pattern with only two junctions [35] . These observations are consistent with a model in which cell selection pressures continue to apply in SCCs (as well as in premalignancy), leading to clonal evolution of cells containing the integration event that confers the greatest competitive advantage [1] .
Breakpoints in the HRHPV genome
In SCC cells, HRHPV breakpoints can occur at any point in the virus genome, although the long control region (LCR) and the oncogenes E6 and E7 are typically retained, owing to the need for expression of virus oncogenes for cell immortalization. Previous studies, including some using NGS [19] , suggested that E2 was most often disrupted during integration, leading to loss of trans-repression of the HRHPV LCR and subsequent increases in virus oncogene expression [2] . However, the more precise breakpoint mapping and greater sample size provided by NGS datasets have not supported this view [5, 6, 9, 12, 24] .
HPV oncogene expression
RNA-seq has shown that relative expression levels of E6 and E7 can vary according to integration status and site. Analysis of 35 TCGA samples of HNSCC showed that cases with integrated HRHPV (n = 25) generally had a higher E6/E7 transcript level per cell than those with episomal HRHPV (n = 10) [9] . Interestingly, however, the presence of integrated genomes did not always correlate with high virus transcription, in keeping with the findings of other studies [12, 36, 37] and our previous work using the W12 cell model of cervical squamous carcinogenesis [38] [39] [40] . Hence, SCC is not always associated with high virus oncogene expression levels, and may be driven independently of this factor, e.g. through changes in host gene expression (see below). Screening of 84 CSCCs showed that tumours could clearly be separated by whether or not they expressed full-length E6 transcripts [10] . Whereas all tumours expressed spliced E6 transcripts (E6*) and E7 transcripts, only a proportion also expressed full-length E6 or E4 and E5, in which case E6* and E7 were usually expressed at decreased levels. The tumours could also be subdivided into the same groupings based on changes in host gene expression, suggesting that the HRHPV oncogene expression levels were of functional significance [10] . Interestingly, the levels of spliced and unspliced E6 transcripts encoding potentially functional E6 were also found to separate HPV18-positive from HPV16-positive CSCCs [4] . The former showed significantly higher virus oncogene expression levels overall, consistent with a higher virus integration rate (100% versus 75%, respectively) [4] .
Transcription of HRHPV oncogenes occurs from the virus early promoter (P 97 in the case of HPV16), and is dictated by the binding of numerous host transcription factors and virus E2 at the virus LCR (Figure 2) . However, during the integration process, the production of E2 transcripts is usually lost through deletion or truncation of the virus genome, giving rise to deregulated transcription of the HRHPV oncogenes [1, 41] . To determine whether integration results in any changes to the location of transcription start sites (TSSs) across the HRHPV genome, the targeted method of cap-analysis gene expression sequencing has been adopted, in which transcripts are 5 ′ -capped before reverse transcription, sequencing and mapping of the 5 ′ ends to the HRHPV genome [42] . This showed that TSSs are indeed restricted to the canonical P 97 early TSS in integrated HPV16 SCC cell lines (SiHa and CaSki), in contrast to the many TSSs for the episomal genome in W12 cells or a CIN1 sample. Interestingly, the TSSs in the latter group were on both the forward and reverse strands of the virus DNA, although it remains unknown whether any of these novel TSSs produce biologically relevant protein-coding HRHPV transcripts [42] .
Transcription from the HRHPV early promoter produces polycistronic transcripts that must be differentially spliced to produce mRNAs coding for individual virus proteins [1] . NGS has identified splicing patterns that are consistent with earlier data produced by quantitative PCR [43, 44] . In addition, sequencing of all nucleotides from transcripts has allowed greater resolution of their profiles across the HRHPV genome, and has identified tumours and cell lines that do not show the usual HRHPV splicing patterns, including expression of the major virus late gene L1 [7, 10, 12] . Heterogeneity of virus alternative transcripts was also highlighted by single-cell RNA-seq of HeLa cells, in which only one Next-generation sequencing and high-risk HPV integration 15 of eight cells predominantly expressed a full-length E6 coding transcript [18] .
As well as changes to HRHPV splicing patterns, several studies have now confirmed that integration of HRHPV genomes can result in virus-host fusion transcripts [4, 8, 10, 12, 18, 43, 45] . Fusion transcripts may have prolonged half-lives because of the use of host polyadenylation sites, and could therefore result in altered levels of the HRHPV oncoproteins or truncated or fusion proteins with modified biological activity [46] . Fusion transcripts can be produced either by polymerase run-through, which therefore encompasses the virus-host junction, or by splicing that may exclude this region [1] .
Local host genomic rearrangements associated with HRHPV integration
Although it has long been known that HRHPV integration is associated with structural rearrangements in the host genome, there has been debate as to whether rearrangements occur prior to, during or after integration [47, 48] . High rates of local host gene rearrangements and copy number variation have been found at integration sites with DNA-seq [12] , whereas RNA-seq showed that integration also occurred closer to amplified regions than expected by chance (41% of integrants) [8] . In addition, regions of high copy number gain correlated with a greater number of HRHPV genomes [5, 12, 49] . Haplotype-resolved analysis using a complex fosmid clone system showed that HPV18 integration and rearrangement occurred early in the history of HeLa cells and preceded aneuploidy, with the rearrangements being maintained across a number of subsequent clones [11] .
The NGS evidence therefore supports a model in which host genomic rearrangements occur during or after integration, and are associated with HRHPV genome amplification [5, 11, 12] . The DNA looping model [12] incorporates recurrent patterns of focal amplification and rearrangements adjacent to the integration sites, implying that concatemers of host and virus genome become amplified in tandem and reinserted back into the host genome [12] . Interestingly, without reinsertion, this could also lead to the production of extrachromosomal virus-host fusion episomes maintained by the HRHPV origin of replication, which have been proposed following analysis of HNSCC TCGA datasets [9, 36] (Figure 3) . However, NGS has yet to confirm conclusively the presence of these virus-host episomes, owing to the current inability of bioinformatic techniques to distinguish between reads from a circularized sequence and those from a linearized genome.
HPV integration effects on host gene expression
Expression of genes at or near to HRHPV integration sites can be modified in multiple ways. Integration directly into a gene occurs commonly in SCCs, possibly at different rates in different anatomical sites. For CSCC, 42% of all breakpoints were found within genes in one study [5] , whereas, in HRHPV-positive HNSCC, 54% of integrants were found within coding regions, with a further 17% within 20 kb of a gene [9] . These studies led to speculation that integration at, or near to, coding regions might provide a selective advantage through modifications to host gene expression [9] . In some studies, the differences in gene expression associated with integration were often modest, with extensive overlap between expression levels in cases where a gene was involved in an integration event and control cases without such integration [8] . However, integration has also been found to be associated with significant increases in local gene expression [4] , and integration into exons specifically may be associated with very high expression of the relevant gene [8] . One explanation for increased host gene expression is that HRHPV integration is commonly associated with amplification of the local region [7] [8] [9] [10] . Integration-associated gene copy number gains across HRHPV-positive SCCs can vary in magnitude from as low as 1.5-fold up to 248-fold [9, 12] . Discrete intron amplifications have also been observed, one associated with a 28-fold increase in HNSCC of levels of RAD51B exon 8 [9] . Conversely, integration into introns of other genes, including FHIT and LRP1B, has been reported to correlate with decreases in protein levels of the respective genes [5] or a total loss of gene function, as seen in previous non-NGS work [50] . Local deletions have also been found, again ranging widely in size, from as little as 487 bp to as much as 234 kb [12] .
Another way in which integration near to genes can affect gene expression is the subsequent translocation of that region elsewhere in the genome. For example, cases of HRHPV-positive SCC have shown rearrangement of chromosomes 3 and 13 through the site of HRHPV integration, leading to amplification of TPRG1, TP63, and KLF5, and increased expression of the corresponding proteins [8, 9] . The latter two proteins are transcription factors associated with proliferation and epithelial development, and, indeed, TP63 has been associated with CSCC as an oncogene [8] . Other studies have used HeLa cells to show that host genomic changes, including translocations, genome-wide copy number variation, single-nucleotide variants, and deletions, led to cognate changes to the host transcriptome and proteome (as assessed by mass spectrometry) [17, 51] .
Gene expression increases have also been shown to occur in the absence of gene amplification. Integration into flanking regions of genes, sometimes as much as 500 kb away, has been found to be associated with large increases in gene transcription, e.g. affecting MYC and HMGA2 [5, 8] . Although the HRHPV genome may integrate into a distal host enhancer region and thereby affect host expression levels passively, direct effects can also occur. Chromatin interaction analysis with paired-end tag sequencing in HeLa cells, in which NGS has been used to determine contacts between distant regions of the genome through the RNA polymerase II enzyme, has shown that virus integration drives high levels of expression of MYC through three-dimensional interactions with the HPV18 promoter/enhancer over ∼500 kb [11] . The three-dimensional interaction between the site of HPV18 integration at 8q24.21 and MYC can be corroborated with previously published NGS-based chromosome conformation capture (Hi-C) data from HeLa cells [52] . This shows that integration of HPV18 genomes in HeLa cells modified the normal chromatin loops around the 8q24.21 locus, leading to direct contact between virus and MYC sequences (Figure 4 ). An important unanswered question is whether this type of long-range gene modulation occurs commonly in HRHPV integration, or just in carcinoma cells, in which, by definition, the virus integration event observed has provided a competitive advantage over other (non-selected) integration sites.
Equally important may be the effects of different levels of E6/E7 oncoprotein expression on global host gene expression. In the W12 cervical carcinogenesis model system, HPV16 E6 and E7 showed concentration-dependent regulation of a network of host transcriptional interactions, via a limited number of central 'master-regulator' genes [38] . Moreover, significant differences in the host transcriptome were detectable in CSCCs expressing variable levels of E6*, E6 and E7 transcripts [8] . Interestingly, such changes were seen in only a subset of HRHPV-positive HNSCCs, in which gene ontology analysis showed a dedifferentiation signature [10] . A weak correlation was also reported between E7 RNA expression and global DNA methylation patterns, which can affect gene transcription levels [9] . For HNSCC, changes in DNA methylation also correlated with HRHPV status in TCGA samples [53] , and could be used to discriminate between HRHPV integration-positive and integration-negative samples [9] .
Conclusions and future directions
NGS has provided significant new insights into the virus integration events that occur in HRHPV-associated malignancies, and has improved our understanding of the process of integration itself. However, important questions remain that cannot easily be addressed by studying SCC tissue samples and cell lines. Cervical carcinogenesis involves a competitive cell selection process [54, 55] . Multiple integration events are present across the cells of a polyclonal premalignancy, but only one is selected for in SCC. The majority of NGS studies to date have concerned the endpoint of the clonal selection process, by focusing on the HRHPV integrants seen in SCC cells. These investigations have not addressed the dynamic changes that underpin progression from premalignancies to carcinomas. It is difficult to study such processes by cross-sectional analysis of clinical samples, as the key events that precede clonal selection early in cervical carcinogenesis occur in the basal epithelial cells of low-grade premalignant lesions [1] . Such cells would need to be isolated by tissue microdissection, which is technically demanding. A more informative approach remains the use of experimental in vitro models, including the W12 system [55] [56] [57] .
Important groups of unanswered questions that should be addressable by future NGS studies include the following:
1 How commonly do the HRHPV integrants that exist in SCC cells show long-range interactions with distant sites in the host genome? What is the genomic range over which such interactions occur? Are long-range interactions equally common across the spectrum of integrants that exist in premalignant lesions prior to cell selection? Once cells are selected, do the long-range interactions change? 2 What drives selection of cells containing a particular HRHPV integration site from a polyclonal starting population, in which a range of different integration sites is present? What are the relative importances of the host site of integration and the local genes in determining cell selection?
